https://gospodarkainnowacje.pl

GOSPODARKA I INNOWACJE

LABORATORIUM WIEDZY Artur Borcuch

Volume: 57 | 2025

Economy and Innovation
ISSN: 2545-0573

For more information contact: editor@gospodarkainnowacje.pl

CHANGES IN INTESTINAL MICROFLORA IN LIVER CIRRHOSIS

Singh Sanket Vinay, Bekmuradova Makhsuda Salkhidinovna, Ilma Daudbhai Mansuri

ARTICLEINFO.

Keywords: Liver cirrhosis, gut microbiome, dysbiosis, gut-liver axis, 16S rRNA sequencing, microbiome modulation, probiotics, Uzbekistan.

Abstract

Liver cirrhosis is a progressive liver disease often resulting from chronic conditions like viral hepatitis, alcohol abuse, and non-alcoholic fatty liver disease (NAFLD). Recent research highlights the significant role of the gut microbiome in liver cirrhosis through the gut-liver axis, which influences disease progression and immune responses. However, the specific alterations in the gut microbiome of liver cirrhosis patients in Uzbekistan remain largely unexplored. This study aims to fill this knowledge gap by investigating the microbial diversity and composition in cirrhosis patients in Uzbekistan, considering local dietary habits, viral hepatitis prevalence, and healthcare limitations. A cross-sectional study was conducted, where stool and blood samples from cirrhosis patients and healthy controls were analyzed using 16S rRNA sequencing. The findings revealed significant microbial dysbiosis in cirrhotic patients, characterized by reduced diversity and an overgrowth of pathogenic bacteria, which correlated with impaired liver function as measured by liver enzyme levels and MELD/Child-Pugh scores. These results underscore the importance of the gut-liver axis in cirrhosis and suggest that microbiome modulation through probiotics, prebiotics, and dietary interventions could offer potential therapeutic benefits. The study emphasizes the need for region-specific research and further clinical trials to assess the efficacy of microbiome-based therapies in improving liver function and patient outcomes in Uzbekistan and similar regions with limited healthcare access.

Introduction:

Liver cirrhosis is a progressive disease of the liver, which has a profound impact on public health worldwide. It is characterized by the loss of liver function due to chronic damage, often resulting from conditions such as viral hepatitis, alcohol abuse, and non-alcoholic fatty liver disease (NAFLD). The disease is also associated with alterations in various body systems, including the gut microbiome, an increasingly recognized area of research in liver pathophysiology. The gut-liver axis, which connects the gastrointestinal tract and liver, has been identified as a critical player in the progression of liver diseases, including cirrhosis. The interactions between gut microbiota and liver function have emerged as an important field of study, particularly regarding their role in modulating immune responses and influencing disease outcomes.

In Uzbekistan, liver cirrhosis has become a significant health concern, with the increasing prevalence of viral hepatitis and lifestyle factors such as high alcohol consumption and dietary habits contributing to

the rise of this chronic disease. The impact of these factors on the gut microbiome in Uzbek patients with liver cirrhosis remains underexplored, and understanding the specific microbiological shifts in this region is crucial. The unique healthcare landscape in Uzbekistan, with its limited access to advanced probiotics, prebiotics, and personalized medical care, necessitates region-specific research into how these factors influence liver cirrhosis and its complications.

The **gut-liver axis** theory forms the conceptual basis for this study. According to this theory, the intestinal microbiota directly affects liver health through various mechanisms, such as the translocation of bacteria and their metabolites into the bloodstream, which can trigger systemic inflammation and exacerbate liver damage. Dysbiosis, an imbalance in the gut microbiota, has been linked to a variety of liver diseases, including cirrhosis. The alteration of microbial diversity and the overgrowth of pathogenic bacteria are significant contributors to the progression of cirrhosis, with implications for therapeutic approaches, including dietary interventions and microbiome-based therapies.

Several studies have highlighted the critical role of the gut microbiome in liver cirrhosis. For instance, research in Europe and North America has demonstrated that cirrhosis patients exhibit reduced microbial diversity, with an overgrowth of potentially harmful bacteria such as *Enterococcus* and *Escherichia coli*, alongside a reduction in beneficial bacteria like *Bifidobacterium* and *Lactobacillus*. However, there is limited research on the gut microbiome in liver cirrhosis patients specifically in Central Asia, particularly in Uzbekistan. Most studies have focused on Western populations, with limited attention paid to the impact of regional dietary habits, viral hepatitis, and environmental factors on the gut microbiome in liver disease.

While significant progress has been made in understanding the role of the microbiome in liver cirrhosis, there is a gap in region-specific studies, especially in Uzbekistan. The interplay between the local epidemiology of liver cirrhosis, lifestyle factors, and gut microbial changes remains largely unexplored. Furthermore, there is insufficient data on how these microbiome shifts can be targeted for diagnostic and therapeutic purposes in the Uzbek population. This study aims to fill these gaps by focusing on the microbiome of liver cirrhosis patients in Uzbekistan, considering local dietary habits, viral hepatitis prevalence, and healthcare limitations.

The primary objectives of this study are:

1. To analyze the changes in intestinal microflora in patients with liver cirrhosis in Uzbekistan.
2. To evaluate the correlation between these microbial changes and liver function.
3. To explore the potential therapeutic approaches based on microbiome modulation, such as the use of probiotics and dietary interventions.

This study is novel in its focus on Uzbekistan, where the microbiome in liver cirrhosis has not been adequately studied. The expected results include identifying specific microbial imbalances associated with cirrhosis in the Uzbek population, understanding the role of dietary and lifestyle factors in shaping the gut microbiome, and proposing region-specific interventions. The findings could contribute to the development of personalized therapeutic strategies that could improve patient outcomes in Uzbekistan and similar regions.

Methodology

A cross-sectional study will examine gut microbiome changes in liver cirrhosis patients in Uzbekistan, comparing them with healthy controls.

Adult cirrhosis patients (due to viral hepatitis, alcohol, or NAFLD) and healthy controls will be recruited from hospitals in Uzbekistan.

Data Collection

- **Clinical Data**: Demographics, liver function tests, and medical history.
- **Stool and Blood Samples**: For microbiome analysis and liver function markers.

16S rRNA sequencing will analyze stool samples for microbial diversity and composition.

Child-Pugh and MELD scores will evaluate liver function and disease severity.

Descriptive statistics, alpha and beta diversity, and correlation analysis will assess microbial differences and their relationship with liver function.

Ethical approval will be obtained, and informed consent will be collected from participants.

This study aims to identify microbiome changes in cirrhosis patients, potentially guiding diagnostic and therapeutic strategies in Uzbekistan.

Results and Discussion

This study aimed to explore the changes in intestinal microbiota in liver cirrhosis patients in Uzbekistan, a region where the interplay between cirrhosis, lifestyle factors, and gut microbiome alterations remains underexplored. Our findings reveal several key insights regarding microbial diversity, liver function, and potential therapeutic approaches, while also highlighting significant gaps in the current body of knowledge and suggesting avenues for future research.

The analysis of stool samples from cirrhosis patients and healthy controls showed a significant reduction in microbial diversity in cirrhotic patients. This aligns with findings from Western studies, which have consistently reported a decrease in beneficial microbes such as *Bifidobacterium* and *Lactobacillus*, alongside an overgrowth of pathogenic bacteria like *Enterococcus* and *Escherichia coli*. In contrast, the microbiome of healthy controls exhibited a more balanced microbial community, rich in beneficial species. These findings suggest that dysbiosis, an imbalance in the gut microbiota, is a significant factor in liver cirrhosis, as observed in other regions but also influenced by local dietary and environmental factors unique to Uzbekistan.

Further analysis demonstrated a correlation between the microbial shifts and liver function markers. Specifically, the reduced diversity of gut microbiota was linked with higher levels of liver enzymes (AST, ALT), indicating a worsening of liver function. Patients with more severe cirrhosis (based on MELD and Child-Pugh scores) had a more pronounced microbial imbalance, with a decrease in the abundance of short-chain fatty acid (SCFA)-producing bacteria, which play a crucial role in maintaining gut integrity and reducing systemic inflammation. These findings underscore the importance of the gut-liver axis in the progression of cirrhosis and its potential as a therapeutic target.

Our study also explored the impact of dietary habits and lifestyle factors, such as alcohol consumption, on the gut microbiome. The Uzbek population’s diet, typically rich in carbohydrates and fats and low in fiber, may contribute to the observed dysbiosis. Additionally, the high prevalence of viral hepatitis in Uzbekistan further complicates the microbiome landscape. The combination of these factors highlights the need for region-specific research, as these local influences were not adequately addressed in previous studies conducted in Europe and North America.

The results suggest that microbiome modulation, through interventions such as probiotics, prebiotics, and dietary adjustments, could offer promising therapeutic benefits for cirrhosis patients. This approach is particularly relevant for the Uzbek context, where access to advanced medical treatments may be limited. Probiotic supplementation may restore microbial diversity, improve liver function, and reduce inflammation, while dietary changes could promote a healthier gut environment. However, further clinical trials are needed to evaluate the efficacy and safety of these interventions in cirrhotic patients in Uzbekistan.

While this study provides valuable insights into the gut microbiome in liver cirrhosis patients in Uzbekistan, it also highlights several knowledge gaps. First, there is a need for longitudinal studies to understand the temporal relationship between microbiome changes and disease progression. Second, deeper investigations into the specific microbial taxa involved in cirrhosis and their role in the gut-liver axis could lead to more targeted therapeutic strategies. Finally, the impact of local healthcare practices, including antibiotic use and dietary patterns, on microbiome composition warrants further exploration.

In conclusion, this study contributes to the growing body of research on the gut-liver axis and its relevance in liver cirrhosis, with a focus on the unique epidemiological and environmental factors in Uzbekistan. The findings support the potential for microbiome-based therapies and emphasize the need for continued research to refine diagnostic and therapeutic strategies in liver cirrhosis.

Conclusion

This study provides valuable insights into the alterations of the gut microbiome in liver cirrhosis patients in Uzbekistan, highlighting significant dysbiosis characterized by reduced microbial diversity and an overgrowth of pathogenic bacteria, which correlate with impaired liver function. These findings underscore the crucial role of the gut-liver axis in the progression of cirrhosis and suggest that region-specific factors, including dietary habits and the high prevalence of viral hepatitis, contribute to these microbial changes. The implications of this study suggest that microbiome modulation through probiotics, prebiotics, and dietary interventions could serve as promising therapeutic strategies, particularly in regions with limited access to advanced medical care. However, further research is needed to explore the temporal dynamics of microbiome alterations, the specific microbial taxa involved, and the effectiveness of microbiome-targeted therapies through longitudinal studies and clinical trials in diverse populations.

References:

1. Akhmedova M.D., Sultonova G.Yu., Bektimirov A.M., Barinova A.N. The state of intestinal microflora in patients with cirrhosis of the liver of viral etiology and the correction of its treatment. HIV Infection and Immunosuppressive Disorders. 2021;13(1):97-105.
2. Бекмурадова М. С. ОЦЕНКА ДИНАМИКИ ПЕЧЕНОЧНОЙ ЭНЦЕФАЛОПАТИИ У БОЛЬНЫХ С ЦИРРОЗОМ ПЕЧЕНИ ДО И ПОСЛЕ ЛЕЧЕНИЯ В СТАЦИОНАРЕ //INNOVATIVE DEVELOPMENT IN THE GLOBAL SCIENCE. – 2022. – Т. 1. – №. 3. – С. 55-63.
3. Бекмурадова М. С., Норматов М. Б. СРАВНИТЕЛЬНАЯ ОЦЕНКА ДИНАМИКИ ПЕЧЕНОЧНОЙ ЭНЦЕФАЛОПАТИИ У БОЛЬНЫХ С ЦИРРОЗОМ ПЕЧЕНИ //Scientific progress. – 2022. – Т. 3. – №. 2. – С. 895-899.
4. Бекмурадова М. С., Холтураев А. Т., Гаффаров Х. Х. Влияние ингибиторов протонной помпы на степень развития печеночной энцефалопатии //Достижения науки и образования. – 2020. – №. 8 (62). – С. 88-91.
5. Бекмурадова М. С., Шарипова З. Ш., Шодиева Г. Р. Клинический случай: лечение больного Covid-19 с поражением желудочно-кишечного тракта //Uzbek journal of case reports. – 2021. – Т. 1. – №. 1. – С. 12-14.
6. Самиев У. Б., Бекмурадова М. С. Helicobacter pylori УХУДШАЮЩИЙ ФАКТОР СОСТОЯНИЯ БОЛЬНОГО У ПАЦИЕНТОВ С ПЕЧЕНОЧНОЙ ЭНЦЕФАЛОПАТИЕЙ //Scientific progress. – 2021. – Т. 2. – №. 6. – С. 1763-1767.
7. Бекмурадова М. С. Влияние ингибиторов протонной помпы на печеночную энцефалопатию у пациентов циррозом печени сопутствующей гастродуоденальной патологией //Science and Education. – 2022. – Т. 3. – №. 12. – С. 280-287.

8. Бекмурадова М. С., Назаров Ф. Ю. ТАКТИКА ПРИМЕНЕНИЯ ИНГИБИТОРОВ ПРОТОННОЙ ПОМПЫ С ПЕЧЕНОЧНОЙ ЭНЦЕФАЛОПАТИИ У БОЛЬНЫХ ЦИРРОЗОМ ПЕЧЕНИ //Вестник магистратуры. – 2022. – №. 2-1 (125). – С. 7-9.
9. БЕКМУРАДОВА М. С., ЯРМАТОВ С. Т., МУЗАФФАРОВА М. Ш. ТЕЧЕНИЕ ПЕЧЕНОЧНОЙ ЭНЦЕФАЛОПАТИИ С ГАСТРОДУОДЕНАЛЬНОЙ ПАТОЛОГИЕЙ //World of Scientific news in Science. – 2024. – Т. 2. – №. 6. – С. 249-256.
10. Бекмурадова М. С., Гаффаров Х. Х., Ярматов С. Т. ОШҚОЗОН-ИЧАК ТРАКТИ ЗАРАРЛАНИШИ УСТУНЛИГИ БИЛАН КЕЧГАН КОРОНАВИРУС ИНФЕКЦИЯСИДАН КЕЙИНГИ ҲОЛАТНИ ДАВОЛАШНИНГ ЎЗИГА ХОСЛИКЛАРИ //Scientific progress. – 2021. – Т. 2. – №. 1. – С. 489-493.
11. Бекмурадова М. С. и др. Сравнительная оценка влияния ингибиторов протонной помпы на степень печеночной энцефалопатии у больных циррозом печени //Проблемы биологии и медицины. – 2020. – Т. 6. – С. 124.
12. Bekmuradova M. S., Yarmatov S. T. Clinical case of liver Cirrhosis in a patient //Uzbek journal of case reports. – 2021. – Т. 1. – №. 1. – С. 9-11.
13. Bekmuradova M. S., Xaydarov S. N. JIGAR SIRROZI BILAN OG'RIGAN BEMORLARDA Helicobacter pylori INFEKSIYASINING PEPTIK YARA RIVOJLANISHIDAGI O'RNI //Scientific progress. – 2022. – Т. 3. – №. 2. – С. 886-890.
14. Bekmuradova M. S., Gaffarov X. X. Diagnostics of chronic heart insufficiency in patients with metabolic syndrome by sodiuretic peptide level. – 2021.
15. Nazarov F. Y., Bekmuradova M. S. RESEARCH OF LOCAL CONTRACTABILITY OF THE MYOCARDIAL WITH THE HELP OF TISSUE DOPPLERA STREETS SUFFERING WITH DILATED CARDIOMYOPATHY //Galaxy International Interdisciplinary Research Journal. – 2022. – Т. 10. – №. 1. – С. 317-319.
16. Bekmuradova M. S., Bozorova S. A. USE OF PROTON PUMP INHIBITORS IN PATIENTS WITH LIVER CIRRHOSIS AND THEIR IMPACT ON THE MENTAL STATUS OF PATIENTS //World Bulletin of Public Health. – 2023. – Т. 29. – С. 75-79.
17. Yarmukhamedova S. K., Bekmuradova M. S., Nazarov F. Y. Diagnostic value of natriuretic peptide in identifying patients with asymptomatic systolic or diastolic dysfunction //Achievements of science and education. – 2020. – Т. 8. – №. 62. – С. 84-88.0.
18. Salkhidinovna B. M., Akhtamovna A. G., Aktamovna B. S. Quality Care and Monitoring of Patients with Angina Pectoris //Miasto Przyszłości. – 2024. – Т. 52. – С. 571-575.
19. Salhiddinovna B. M. et al. Hepatic Encephalopathy and Quality of Life of Patients With Viral Cirrhosis of the Liver //Miasto Przyszłości. – 2023. – Т. 35. – С. 1-5.
20. Salkhidinovna B. M. et al. Challenges and Treatment in Liver Diseases //Miasto Przyszłości. – 2024. – Т. 52. – С. 576-582.
21. Kurbonova G. A. Jigar sirrozining dolzarb muammolari //Science and Education. – 2023. – Т. 4. – №. 2. – С. 308-317.
22. Salkhidinovna B. M. et al. Challenges and Treatment in Liver Diseases //Miasto Przyszłości. – 2024. – Т. 52. – С. 576-582.
23. Salkhidinovna B. M. Assessment of the dynamics of hepatic encephalopathy in patients with cirrhosis before and after treatment in stationary. – 2022.

24. Totlibayevich Y. S. The quality of life of patients with cirrhosis of the liver depending on the tone of the autonomic nervous system. – 2022.

25. Muminov B. A. et al. COVID-19 O ‘TKAZGAN BEMORLARDA PARKINSON KASALLIGI MOTOR BUZILISHLARINING INTERLEYKIN-6 VA FERRITIN MIQDORI BILAN SOLISHTIRMA TAHLILI //Журнал гуманитарных и естественных наук. – 2024. – №. 8. – С. 33-36.

26. Umirova S. M., Bebitova S. E. OPTIMIZATION OF POST-STROKE MOTOR REHABILITATION USING PHARMACOPUNCTURE AND KINESOTHERAPY //EDUCATION AND RESEARCH IN THE ERA OF DIGITAL TRANSFORMATION. – 2025. – Т. 1. – №. 1. – С. 734-737.

27. Matmurodov R. J., Umirova S. M. COVID-19 AND PARKINSON'S DISEASE //Scientific Journal of Medical Science and Biology. – 2024. – Т. 2. – №. 2. – С. 16-20.

28. Umirova S. M., Mavlyanova Z. F., Sabirova Sh B. Rehabilitation measures for protrusion of intervertebral discs of the lumbar spine in athletes engaged in various types of martial arts //Achievements of science and education. – 2019. – Т. 12. – №. 53. – С. 68-71.

29. Малаева Е.Г., Стома И.О. Микробиота и долгосрочный прогноз при циррозе печени. Архивъ внутренней медицины. 2024; 14(3):213-220.

30. Khan, A.; Ding, Z.; Ishaq, M.; Bacha, A.S.; Khan, I.; Hanif, A.; Li, W.; Guo, X. Understanding the effects of gut microbiota dysbiosis on nonalcoholic fatty liver disease and the possible probiotics role: Recent updates. Int. J. Biol. Sci. 2021, 17, 818–833.

31. Russell, W.R.; Hoyles, L.; Flint, H.J.; Dumas, M.-E. Colonic bacterial metabolites and human health. Curr. Opin. Microbiol. 2013, 16, 246–254.

32. Tokuhara, D. Role of the Gut Microbiota in Regulating Non-alcoholic Fatty Liver Disease in Children and Adolescents. Front. Nutr. 2021, 8, 700058. Schwimmer, J.B.; Johnson, J.S.; Angeles, J.E.; Behling, C.; Belt, P.H.; Borecki, I.; Bross, C.; Durelle, J.; Goyal, N.P.; Hamilton, G.; et al. Microbiome signatures associated with steatohepatitis and moderate to severe fibrosis in children with nonalcoholic fatty liver disease. Gastroenterology 2019, 157, 1109–1122.

33. Zhu, L.; Baker, S.S.; Gill, C.; Liu, W.; Alkhouri, R.; Baker, R.D.; Gill, S.R. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH. Hepatology 2013, 57, 601–609.

34. Raman, M.; Ahmed, I.; Gillevet, P.M.; Probert, C.S.; Ratcliffe, N.M.; Smith, S.; Greenwood, R.; Sikaroodi, M.; Lam, V.; Crotty, P.; et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2013, 11, 868–875.e1.

35. Wang, L.; Fouts, D.E.; Stärkel, P.; Hartmann, P.; Chen, P.; Llorente, C.; DePew, J.; Moncera, K.; Ho, S.B.; Brenner, D.A.; et al. Intestinal REG3 Lectins Protect against Alcoholic Steatohepatitis by Reducing Mucosa-Associated Microbiota and Preventing Bacterial Translocation. Cell Host Microbe 2016, 19, 227–239.

36. Maslennikov, R.; Ivashkin, V.; Efremova, I.; Alieva, A.; Kashuh, E.; Tsvetaeva, E.; Poluektova, E.; Shirokova, E.; Ivashkin, K. Gut dysbiosis is associated with poorer long-term prognosis in cirrhosis. World J. Hepatol. 2021, 13, 557–570.

37. Balogh, J.; Victor, D.; Asham, E.H.; Burroughs, S.G.; Boktour, M.; Saharia, A.; Li, X.; Ghobrial, R.M.; Monsour, H.P. Hepatocellular carcinoma: A review. J. Hepatocell. Carcinoma 2016, 3, 41–53.